Impaired fitness of drug-resistant malaria parasites: Evidence and implication on drug-deployment policies

Hamza A. Babiker, Ian M. Hastings, Göte Swedberg

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Malaria, a leading parasitic disease, inflicts an enormous toll on human lives and is caused by protozoal parasites belonging to the genus Plasmodium. Antimalarial drugs targeting essential biochemical processes in the parasite are the primary resources for management and control. However, the parasite has established mutations, substantially reducing the efficacy of these drugs. First-line therapy is faced the with the consistent evolution of drug-resistant genotypes carrying these mutations. However, drug-resistant genotypes are likely to be less fit than the wild-type, suggesting that they might disappear by reducing the volume of drug pressure. A substantial body of epidemiological evidence confirmed that the frequency of resistant genotypes wanes when active drug selection declines. Drug selection on the parasite genome that removes genetic variation in the vicinity of drug-resistant genes (hitch-hiking) is common among resistant parasites in the field. This can further disadvantage drug-resistant strains and limit their variability in the face of a mounting immune response. Attempts to provide unequivocal evidence for the fitness cost of drug resistance have monitored the outcomes of laboratory competition experiments of deliberate mixtures of sensitive and resistant strains, in the absence of drug pressure, using isogenic clones produced either by drug selection or gene manipulation. Some of these experiments provided inconclusive results, but they all suggested reduced fitness of drug-resistant clones in the absence of drug pressure. In addition, biochemical ana lyses provided clearer information demonstrating that the mutation of some antimalarial-targeted enzymes lowers their activity compared with the wild-type enzyme. Here, we review current evidences for the disadvantage of drug-resistance mutations, and discuss some strategies of drug deployment to maximize the cost of resistance and limit its spread.

Original languageEnglish
Pages (from-to)581-593
Number of pages13
JournalExpert Review of Anti-Infective Therapy
Volume7
Issue number5
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Malaria
Parasites
Pharmaceutical Preparations
Mutation
Genotype
Antimalarials
Drug Resistance
Pressure
Biochemical Phenomena
Clone Cells
Costs and Cost Analysis
Parasitic Diseases
Plasmodium
Enzymes
Drug Delivery Systems
Genes
Genome

Keywords

  • Chloroquine
  • Drug-resistant genotype
  • Fitness cost
  • Plasmodium chabaudi
  • Plasmodium falciparum
  • Pyrimethamine
  • Sulfadoxine

ASJC Scopus subject areas

  • Microbiology
  • Virology
  • Infectious Diseases
  • Microbiology (medical)

Cite this

Impaired fitness of drug-resistant malaria parasites : Evidence and implication on drug-deployment policies. / Babiker, Hamza A.; Hastings, Ian M.; Swedberg, Göte.

In: Expert Review of Anti-Infective Therapy, Vol. 7, No. 5, 06.2009, p. 581-593.

Research output: Contribution to journalArticle

@article{bf2ab7f7d4fe4786b3b46583cac0333b,
title = "Impaired fitness of drug-resistant malaria parasites: Evidence and implication on drug-deployment policies",
abstract = "Malaria, a leading parasitic disease, inflicts an enormous toll on human lives and is caused by protozoal parasites belonging to the genus Plasmodium. Antimalarial drugs targeting essential biochemical processes in the parasite are the primary resources for management and control. However, the parasite has established mutations, substantially reducing the efficacy of these drugs. First-line therapy is faced the with the consistent evolution of drug-resistant genotypes carrying these mutations. However, drug-resistant genotypes are likely to be less fit than the wild-type, suggesting that they might disappear by reducing the volume of drug pressure. A substantial body of epidemiological evidence confirmed that the frequency of resistant genotypes wanes when active drug selection declines. Drug selection on the parasite genome that removes genetic variation in the vicinity of drug-resistant genes (hitch-hiking) is common among resistant parasites in the field. This can further disadvantage drug-resistant strains and limit their variability in the face of a mounting immune response. Attempts to provide unequivocal evidence for the fitness cost of drug resistance have monitored the outcomes of laboratory competition experiments of deliberate mixtures of sensitive and resistant strains, in the absence of drug pressure, using isogenic clones produced either by drug selection or gene manipulation. Some of these experiments provided inconclusive results, but they all suggested reduced fitness of drug-resistant clones in the absence of drug pressure. In addition, biochemical ana lyses provided clearer information demonstrating that the mutation of some antimalarial-targeted enzymes lowers their activity compared with the wild-type enzyme. Here, we review current evidences for the disadvantage of drug-resistance mutations, and discuss some strategies of drug deployment to maximize the cost of resistance and limit its spread.",
keywords = "Chloroquine, Drug-resistant genotype, Fitness cost, Plasmodium chabaudi, Plasmodium falciparum, Pyrimethamine, Sulfadoxine",
author = "Babiker, {Hamza A.} and Hastings, {Ian M.} and G{\"o}te Swedberg",
year = "2009",
month = "6",
doi = "10.1586/ERI.09.29",
language = "English",
volume = "7",
pages = "581--593",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Impaired fitness of drug-resistant malaria parasites

T2 - Evidence and implication on drug-deployment policies

AU - Babiker, Hamza A.

AU - Hastings, Ian M.

AU - Swedberg, Göte

PY - 2009/6

Y1 - 2009/6

N2 - Malaria, a leading parasitic disease, inflicts an enormous toll on human lives and is caused by protozoal parasites belonging to the genus Plasmodium. Antimalarial drugs targeting essential biochemical processes in the parasite are the primary resources for management and control. However, the parasite has established mutations, substantially reducing the efficacy of these drugs. First-line therapy is faced the with the consistent evolution of drug-resistant genotypes carrying these mutations. However, drug-resistant genotypes are likely to be less fit than the wild-type, suggesting that they might disappear by reducing the volume of drug pressure. A substantial body of epidemiological evidence confirmed that the frequency of resistant genotypes wanes when active drug selection declines. Drug selection on the parasite genome that removes genetic variation in the vicinity of drug-resistant genes (hitch-hiking) is common among resistant parasites in the field. This can further disadvantage drug-resistant strains and limit their variability in the face of a mounting immune response. Attempts to provide unequivocal evidence for the fitness cost of drug resistance have monitored the outcomes of laboratory competition experiments of deliberate mixtures of sensitive and resistant strains, in the absence of drug pressure, using isogenic clones produced either by drug selection or gene manipulation. Some of these experiments provided inconclusive results, but they all suggested reduced fitness of drug-resistant clones in the absence of drug pressure. In addition, biochemical ana lyses provided clearer information demonstrating that the mutation of some antimalarial-targeted enzymes lowers their activity compared with the wild-type enzyme. Here, we review current evidences for the disadvantage of drug-resistance mutations, and discuss some strategies of drug deployment to maximize the cost of resistance and limit its spread.

AB - Malaria, a leading parasitic disease, inflicts an enormous toll on human lives and is caused by protozoal parasites belonging to the genus Plasmodium. Antimalarial drugs targeting essential biochemical processes in the parasite are the primary resources for management and control. However, the parasite has established mutations, substantially reducing the efficacy of these drugs. First-line therapy is faced the with the consistent evolution of drug-resistant genotypes carrying these mutations. However, drug-resistant genotypes are likely to be less fit than the wild-type, suggesting that they might disappear by reducing the volume of drug pressure. A substantial body of epidemiological evidence confirmed that the frequency of resistant genotypes wanes when active drug selection declines. Drug selection on the parasite genome that removes genetic variation in the vicinity of drug-resistant genes (hitch-hiking) is common among resistant parasites in the field. This can further disadvantage drug-resistant strains and limit their variability in the face of a mounting immune response. Attempts to provide unequivocal evidence for the fitness cost of drug resistance have monitored the outcomes of laboratory competition experiments of deliberate mixtures of sensitive and resistant strains, in the absence of drug pressure, using isogenic clones produced either by drug selection or gene manipulation. Some of these experiments provided inconclusive results, but they all suggested reduced fitness of drug-resistant clones in the absence of drug pressure. In addition, biochemical ana lyses provided clearer information demonstrating that the mutation of some antimalarial-targeted enzymes lowers their activity compared with the wild-type enzyme. Here, we review current evidences for the disadvantage of drug-resistance mutations, and discuss some strategies of drug deployment to maximize the cost of resistance and limit its spread.

KW - Chloroquine

KW - Drug-resistant genotype

KW - Fitness cost

KW - Plasmodium chabaudi

KW - Plasmodium falciparum

KW - Pyrimethamine

KW - Sulfadoxine

UR - http://www.scopus.com/inward/record.url?scp=68049117184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049117184&partnerID=8YFLogxK

U2 - 10.1586/ERI.09.29

DO - 10.1586/ERI.09.29

M3 - Article

C2 - 19485798

AN - SCOPUS:68049117184

VL - 7

SP - 581

EP - 593

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 5

ER -